• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

ADB and DNDi sign MoU to advance healthcare cooperation on neglected diseases in Asia and the Pacific

Home > News

ADB and DNDi sign MoU to advance healthcare cooperation on neglected diseases in Asia and the Pacific

5 Aug 2025

The Asian Development Bank (ADB) and the Drugs for Neglected Diseases initiative (DNDi) have signed a Memorandum of Understanding (MoU) to formalize a non-exclusive framework of cooperation to promote programmes and projects in the field of healthcare across Asia and the Pacific. The collaboration aims to jointly focus on shared strategic and operational priorities, including neglected diseases with increasing prevalence due to climate change such as leishmaniasis and dengue; pandemic preparedness; and technology transfer for local manufacturing. 

The MoU was signed by Ayako Inagaki, Senior Director, Human and Social Development Sector Office, ADB; Dr Kavita Singh, Continental Lead Asia and South Asia Director, DNDi, and Ms Thi Hanh Cao, External Relations Director, DNDi. 

‘This collaboration with DNDi supports ADB’s efforts to help developing member countries in Asia and the Pacific address the health impacts of neglected diseases and improve preparedness for future pandemics,’ said Ayako Inagaki, Senior Director, Human and Social Development Sector Office, ADB.

The MoU also focuses on enhancing gender-responsive research and development and developing therapeutics for pediatric populations living with neglected diseases. It commits to ensuring that innovations in control, diagnosis, therapeutics, and surveillance of neglected diseases are sex and gender-responsive, using sex-disaggregated data and gender analysis to understand and address differences in exposure risks, disease susceptibilities, prevention and treatment behaviors, and preferences in product design.

‘This partnership with ADB reflects our shared focus on advancing, scaling, and improving access to innovations for climate-sensitive diseases across Asia and the Pacific. Dengue, in particular, remains a growing challenge, impacting many countries and demands urgent attention. This joint effort also prioritizes the critical importance of technology transfer for local manufacturing and the need to build therapeutic coalitions for pandemic preparedness,’ said Dr Kavita Singh, Asia Continental Lead & Office Director, DNDi.

Ayako Inagaki, ADB’s Senior Director for Human and Social Development Sector Office, and Dr Kavita Singh, DNDi’s Asia Continental Lead & Office Director, signing the MoU at the 1st INSPIRE Health Forum.

Partnership Asia

Read, watch, share

Loading...
Publications
6 Nov 2026

Extreme heat and climate-sensitive infectious diseases

News
2 Nov 2026

Project to develop dengue treatment pre-selected by the Global Coalition for Local and Regional Production, Innovation, and Equitable Access

close up of a scientist holding tools they are wearing blue gloves
Press releases
29 Oct 2026

DNDi welcomes GHIT Fund’s support for innovative approaches to improve success in Chagas disease drug discovery with Nagasaki University, the University of Dundee, and Eisai 

Press releases
27 Oct 2026

Kenya becomes first African country to join the Dengue Alliance

News
9 Oct 2026

DNDi 2026 Projects of the Year recognize teams and partners for their work to advance an open-science antiviral for future coronavirus pandemics and a single-dose treatment for sleeping sickness

Press releases
6 Oct 2026

Ghana’s KNUST and DNDi partner to accelerate drug discovery for neglected diseases in Africa

Statements
25 Sep 2026

DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly

News
15 Sep 2026

New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D

VIEW ALL

Help neglected patients

To date, we have delivered seventeen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license